In this episode:

• PSA is key for monitoring metastatic prostate cancer, especially on hormone therapy—rising levels may signal treatment resistance
• MRI can contribute to improved diagnosis, reduce unnecessary biopsies, and help target lesions
• Risk has dropped thanks to better biopsies, active surveillance, and focal therapy

• Consider whether transperineal biopsy might be preferred over transrectal

Expert: A/Prof Jeremy Grummet, Urologist

This podcast is intended to be medical advice that is designed for health professionals only. We do not recommend you use this podcast as a substitute for a consult with a qualified health professional.

See omnystudio.com/listener for privacy information.